Incidence and outcome of invasive candidiasis in intensive care units ( ICUs ) in Europe

Background: The objective of this study was to assess the cumulative incidence of invasive candidiasis (IC) in intensive care units (ICUs) in Europe. Methods: A multinational, multicenter, retrospective study was conducted in 23 ICUs in 9 European countries, representing the first phase of the candidemia/intra-abdominal candidiasis in European ICU project (EUCANDICU). Results: During the study period, 570 episodes of ICU-acquired IC were observed, with a cumulative incidence of 7.07 episodes per 1000 ICU admissions, with important between-center variability. Separated, non-mutually exclusive cumulative incidences of candidemia and IAC were 5.52 and 1.84 episodes per 1000 ICU admissions, respectively. Crude 30-day mortality was 42%. Age (odds ratio [OR] 1.04 per year, 95% CI 1.02–1.06, p < 0.001), severe hepatic failure (OR 3.25, 95% 1.31–8.08, p 0.011), SOFA score at the onset of IC (OR 1.11 per point, 95% CI 1.04–1.17, p 0.001), and septic shock (OR 2.12, 95% CI 1.24–3.63, p 0.006) were associated with increased 30-day mortality in a secondary, exploratory analysis. Conclusions: The cumulative incidence of IC in 23 European ICUs was 7.07 episodes per 1000 ICU admissions. Future in-depth analyses will allow explaining part of the observed between-center variability, with the ultimate aim of helping to improve local infection control and antifungal stewardship projects and interventions.

[1]  S. Bailly,et al.  ICU-acquired candidaemia in France: Epidemiology and temporal trends, 2004-2013 - A study from the REA-RAISIN network. , 2017, The Journal of infection.

[2]  J. Rello,et al.  Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study , 2017, Intensive Care Medicine.

[3]  M. Antonelli,et al.  Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study , 2016, Critical Care.

[4]  S. Bailly,et al.  Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study , 2016, Annals of Intensive Care.

[5]  M. Antonelli,et al.  A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality , 2015, Intensive Care Medicine.

[6]  M. Antonelli,et al.  A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality , 2014, Intensive Care Medicine.

[7]  A. Shorr,et al.  A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts , 2013, Intensive Care Medicine.

[8]  A. Corona,et al.  Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006–2008) , 2012, Mycoses.

[9]  Elie Azoulay,et al.  Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study* , 2011, Critical care medicine.

[10]  Jordi Rello,et al.  International study of the prevalence and outcomes of infection in intensive care units. , 2009, JAMA.

[11]  C. Putensen,et al.  Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment , 2009, Intensive Care Medicine.

[12]  E. Bouza,et al.  Epidemiology of candidemia in intensive care units. , 2008, International journal of antimicrobial agents.

[13]  C. Putensen,et al.  Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis , 2008, Intensive Care Medicine.